Estudo randomizado | Reloxaliase vs. placebo na hiperoxalúria entérica.
10 Mai, 2022 | 14:14hRandomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria – NEJM Evidence
Comentário no Twitter
Patients with enteric hyperoxaluria received reloxaliase, an enzyme that degrades oxalate in the GI tract, or placebo with food for 4 weeks. There was a greater reduction in urinary oxalate excretion with reloxaliase. https://t.co/x7m12QHyWX#NephTwitter #UroSoMe #ClinicalTrials pic.twitter.com/rzCpd6YfLM
— NEJM Evidence (@NEJMEvidence) May 6, 2022